Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
MYLAN faces an increasing backlash over its handling of the EpiPen pricing controversy, as a top proxy adviser urged shareholders to oust the drugmaker's board.
Institutional Shareholder Services (ISS) said that the company's directors had failed to stop "significant